| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695227 | Gynecologic Oncology | 2017 | 5 Pages |
Abstract
ABT-888 plus LDFWAR is tolerable with gastrointestinal symptoms, fatigue and myelosuppression as the most common toxicities. The single observed objective response was in a germline BRCA mutated, platinum-sensitive patient.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kim A. Reiss, Joseph M. Herman, Deborah Armstrong, Marianna Zahurak, Anthony Fyles, Anthony Brade, Michael Milosevic, Laura A. Dawson, Angela Scardina, Patricia Fischer, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen, Sarah Temkin,